Last reviewed · How we verify
Long-term Immunogenicity of a Live Herpes Zoster Vaccine in Systemic Lupus Erythematosus (SLE) Patients
A recent randomized controlled trial (RCT) from our group has demonstrated safety and immune response (both humoral and cell-mediated) of the live-attenuated herpes zoster (HZ) vaccine (Zostavax) in stable systemic lupus erythematosus (SLE) patients with a previous history of HZ or varicella infection. An important research question is whether the immunogenicity of the HZ vaccine in SLE patients is long-lasting. There is no information in the literature regarding the long-term immunogenicity and safety of Zostavax in SLE patients. This prompts the current extension study which is planned to evaluate the long-term immunogenicity and efficacy of Zostavax in our original patient cohort.
Details
| Lead sponsor | Tuen Mun Hospital |
|---|---|
| Status | COMPLETED |
| Enrolment | 68 |
| Start date | Mon Jun 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun Oct 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Lupus Erythematosus
Interventions
- Immunogenicity
Countries
China